ReviewCureus2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Weight, BMI, and Body Composition in Adults With Type 2 Diabetes Mellitus: A Systematic Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological Management of Diabesity: Current and Emerging Therapies.Current obesity reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a major global health issue, affecting millions and leading to significant healthcare costs. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a potential treatment option. Still, their effects on body weight, body mass index (BMI), and body composition compared to other diabetes medications or placebos remain unclear. This systematic review investigates these effects in adults with T2DM. A comprehensive literature search was conducted from June 20, 2024, to July 5, 2024, across six databases and one register: PubMed, MEDLINE, Cochrane Library (CENTRAL), Europe PMC, ScienceDirect, ClinicalTrials.gov, and EBSCO Open Dissertation, yielding 2,425 records. Following the application of inclusion and exclusion criteria, 13 studies were selected for final analysis, encompassing a sample size of 37,619 participants, adhering to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. The quality of the included studies was assessed using the Cochrane Risk-of-Bias Tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. Results indicate that SGLT2 inhibitors are significantly associated with reductions in body weight and BMI compared to other diabetes medications and placebo. These findings suggest that SGLT2 inhibitors improve glycemic control and facilitate effective weight management, underscoring their potential role in comprehensive diabetes care. Future research should focus on long-term outcomes and the integration of SGLT2 inhibitors into individualized treatment plans for patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.